Chargement en cours...
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) were initially established as second- or third-line treatment of advanced non-small-cell lung cancer (NSCLC). Subsequent studies, including IPASS, OPTIMAL, and EURTAC, have demonstrated that these TKIs are effective first-line t...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2012
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3459550/ https://ncbi.nlm.nih.gov/pubmed/23055691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S26558 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|